About Rezolute, Inc. Common Stock (NV) (RZLT)

Rezolute Inc is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its main clinical asset, Ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism.

RZLT trading today

RZLT has traded between $3.60 and $4.61 in the current session, a range of $1.01. The latest price of $3.83 sits in the middle of that range (23% of the way from low to high). It opened at $3.87, essentially flat to the prior close of $3.87. The volume-weighted average price is $3.93, and the stock is trading below it. Traders often use VWAP as a gauge of whether buyers or sellers have had the better average entry today.

Where RZLT holders stand

StockMarketLoop's Market Position model estimates how the shares traded between 2026-08-16 and 2026-11-14 were bought. Its estimate of the average cost basis is $4.13; at $3.83 the stock trades 7.3% below that level. About 5.7% of those shares are estimated to be held at a profit at the current price. A low figure means most recent buyers are underwater, so rallies can meet selling from holders trying to get back to break even. The densest nearby clusters of cost basis sit around $3.65 (support) and $4.07 (resistance). Roughly 70% of the estimated cost basis lies between $3.79 and $4.54, and 90% between $3.63 and $4.84.

This is a model estimate built from price and volume history, not a record of actual positions.

How to read this page

Quote figures come from StockMarketLoop's market data feed and may be delayed; the timestamp in the summary above shows when they were observed. Company details come from public reference data. The cost-basis section is a statistical model, not a forecast. Nothing here is investment advice; see our financial disclaimer and editorial policy.